EMA Authorised: Segluromet (ertugliflozin l-pyroglutamic acid;metformin hydrochloride) — Merck Sharp & Dohme B.V.

View source ↗

Summary

The EMA authorised Segluromet, a fixed-dose combination of ertugliflozin and metformin, for the treatment of type 2 diabetes in adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• SEGLUROMET (ertugliflozin and metformin hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Merck Sharp & Dohme B.V.. Decision date: 21/11/2025